Telix Pharmaceuticals Limited Sponsored ADR TLX 深 滬
等待開盤 04-01 09:30:00 美东时间
9.57
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 9.57
- 總市值 32.44亿
- 52周最高 20.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 6.28
- 委 比 0.00%
- 總股本 3.39亿
- 歷史最高 30.36
- 量 比 0
- 振 幅 0.00%
- 歷史最低 6.28
- 每 手 1
- 風險率 3.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Is Telix Pharmaceuticals Stock Gaining Tuesday?
Telix Pharma's ProstACT study achieves primary objectives, positioning TLX591-Tx as potential first-line treatment for prostate cancer.
03-10 19:01
Reported Earlier, Telix Pharmaceuticals' TLX591-Tx Meets Primary Objectives In ProstACT Global Phase 3 Part 1 Study, No New Safety Signals Observed In mCRPC Patients
Key findings include:Tolerability profile supported by dosimetry and low-grade non-hematologic events.Lesion dosimetry indicates no difference in absorbed dose profile across cohorts.No adverse drug-drug interactions
03-10 15:20
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
Citigroup Maintains Buy on Telix Pharmaceuticals, Raises Price Target to $22.5
Citigroup analyst Laura Sutcliffe maintains Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and raises the price target from $22 to $22.5.
02-25 01:44
Telix Pharma Submits Marketing Authorization Application In Europe For TLX101-Px, Glioma Imaging Candidate
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its
02-18 05:57
Telix Pharmaceuticals Doses First Participant In U.S. For Its BiPASS Study To Evaluate Use Of Commercial PSMA-PET1 Imaging Agents Illuccix, Gozellix For Initial Prostate Cancer Diagnosis Setting
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a
01-17 03:22
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and maintains $20 price target.
2025-12-22 20:12
Telix Pharma Collaborates With Varian To Develop Clinical Applications That Combine Telix's Theranostic Products And External Beam Radiation Therapy
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel
2025-12-10 20:04
Telix Pharma's ZIRCON-X Study Shows TLX250-CDx Imaging Could Alter Clinical Management In Nearly Half of Patients
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab)
2025-11-20 03:03
